Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10942039 | 0.89 | TSHR (0.44) | TSHRDHFROPRM1OPRD1OPRK1 | |
| SCHEMBL9720395 | 0.76 | CA1 (0.41) | SIGMAR1HRH3OPRM1OPRL1CA1 | |
| SCHEMBL6722030 | 0.76 | SIGMAR1 (0.38) | SIGMAR1HRH3CA1CA2CA9 | |
| SCHEMBL2237483 | 0.72 | TSHR (0.41) | TSHRDHFROPRM1OPRD1OPRK1 | |
| SCHEMBL11540623 | 0.72 | TSHR (0.41) | TSHRDHFROPRM1OPRD1OPRK1 | |
| SCHEMBL4315741 | 0.72 | ALDH1A1 (0.44) | TSHRDHFR | |
| SCHEMBL11587465 | 0.72 | TSHR (0.41) | TSHRDHFROPRM1OPRD1OPRK1 | |
| SCHEMBL3985723 | 0.72 | MAOA (0.44) | TSHRDHFROPRM1OPRD1OPRK1 | |
| SCHEMBL11115468 | 0.72 | TSHR (0.41) | TSHRDHFR | |
| SCHEMBL13908147 | 0.70 | KCNA3 (0.48) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040049049-A1 | Stereoselective synthesis of 1,2-disubstituted cycloalkyls | JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049049-A1 | Stereoselective synthesis of 1,2-disubstituted cycloalkyls | CYP8B1, AGTR1, AGTR2 | TSHR 2421/4885DHFR 367/4885SIGMAR1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.